| Cat. No. |
Product Name |
Information |
| PC-Ab1073 |
Anti-human SIGLEC15 mAb, 5G-12
|
Anti-Human SIGLEC15 (5G-12) is a high affinity humanized IgG4 mAb specific for SIGLEC15 (S15, Sialic Acid-Binding Ig-Like Lectin 15), blocks Siglec-15-mediated suppression of murine OT-I responses to 293T-K b OVA-S15 + or OVA 257-264-pulsed mouse primary macrophages, inhibits the growth of established tumors in murine models.. |
| PC-Ab1072 |
Vedolizumab
|
Vedolizumab (MLN-0002) is a humanized monoclonal antibody, which acts against α 4 β 7 integrin heterodimer and blocks the interaction of α4β7 integrin with mucosal address in cell adhesion molecule-1 (MAdCAM-1). Vedolizumab inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) parenchymal tissue, impairs the migration of gut-homing lymphocytes into the mucosa, thereby acting as a gut-selective anti-lymphocyte-trafficking immunomodulator.. |
| PC-Ab1071 |
Adalimumab
|
Adalimumab (D2E7, ABT-D2E7) is a recombinant human IgG1 monoclonal antibody specific for human TNF-α, specifically targets and blocks TNF-alpha which contributes to the inflammation that causes the abscesses, inflammatory nodules, and draining fistulas in hidradenitis suppurativa (HS).. |
| PC-Ab1070 |
Erenumab
|
Erenumab (AMG-334) is a fully human monoclonal antibody that selectively and potently binds to the canonical CGRP (calcitonin gene-related peptide receptor). Erenumab (AMG-334) competes with [(125)I]-CGRP binding to the human CGRP receptor, with a Ki of 0.02 nM. AMG 334 fully inhibited CGRP-stimulated cAMP production with an IC50 of 2.3 nM in cell-based functional assays (human CGRP receptor) and was 5000-fold more selective for the CGRP receptor than other human calcitonin family receptors, inc |
| PC-Ab1069 |
MK-4166
|
MK-4166 is a humanized IgG1 agonist monoclonal antibody targeting GITR. MK-4166 decreased induction and suppressive effects of T regs in vitro In human TIL cultures, MK-4166 induced phosphorylation of NFκB and increased expression of dual specificity phosphatase 6 (DUSP6), indicating that MK-4166 activated downstream NFκB and Erk signaling pathways.. |
| PC-Ab1068 |
Caplacizumab
|
Caplacizumab (ALX0081) is a humanized single variable domain immunoglobulin (nanobody) against the von Willebrand factor (VWF). by targetting the A1 domain of the ultra-large von Willebrand factor which in order inhibits the interaction with the glycoprotein Ib-IX-V receptor in the platelets. Caplacizumab has used to treat acquired thrombotic thrombocytopenic purpura (aTTP).. |
| PC-Ab1067 |
Tislelizumab
|
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. Tislelizumab (BGB-A317) binds to and blocks human PD-1 with high affinity and specificity, shows anti-tumor activity through activation of antibody-dependent macrophage-mediated killing of T effector cells.. |
| PC-Ab1066 |
Omburtamab
|
8H9 is an IgG1 mAb that targets B7-H3, it is broadly reactive with human solid tumors, including embryonal tumors and carcinomas. 131I-omburtamab, a monoclonal antibody called 8H9 linked to a radioactive agent called iodine 131. 8H9 attaches to B7H3 positive tumor cells in a targeted way and delivers iodine 131 to kill them. 8H9 has been successfully used for radioimmunotherapy for patients with B7-H3(+) tumors. In early phase human clinical trials, 131I-8H9 prolongs survival among high risk pat |
| PC-Ab1065 |
Sotigalimab
|
Sotigalimab (APX005M) is a humanized monoclonal antibody that binds CD40 with high affinity and activates antigen presenting cells (dendritic cells, monocytes and B cells) leading to stimulation of cancer-specific T-cell responses. This CD40 monoclonal antibody with chemotherapy induces T-cell-dependent tumour regression in mice and improves survival, triggers a multifaceted immune response that brings several components of the immune system together to attack the cancer.. |
| PC-Ab1064 |
Pertuzumab
|
Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2 and inhibits heterodimerization of HER2 with other HER family members, including EGF receptor (EGFR), HER3, and HER4.. |
| PC-Ab1063 |
Ranibizumab
|
Ranibizumab (Lucentis, RG-6321) is a specific affinity-matured, recombinant, humanized, anti-VEGF antigen-binding antibody fragment (Fab) that binds and neutralizes all the biologically active forms of VEGF-A, an important mediator in the development of choroidal neovascularisation. Ranibizumab was approved by the Food and Drug Administration (FDA) for the treatment of neovascular AMD.. |
| PC-Ab1062 |
Lemzoparlimab
|
Lemzoparlimab (TJ011133 or TJC4) is a fully human, anti-CD47 IgG4 antibody that is endowed with a red blood cell (RBC) sparing property and unique binding epitope, potentially differentiating itself from other CD47 axis targeting therapies. Lemzoparlimab blocks the interaction of CD47 and SIRPα, leading to phagocytosis of various CD47+ tumor cell lines and primary AML cells.. |
